Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis
about
Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialTacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood TransplantationChronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.
P2860
Q33424311-43503426-74EC-4743-9BE3-470F440312ECQ33429827-5C2E637D-8648-4F21-8FF1-97520A371AB3Q34077792-7BF632C5-0C3C-4906-A464-11E62CDD750AQ34272554-4E2C75DE-A5DE-42AF-961D-1642C47445E0Q35231363-51EFA26B-0200-49ED-BD38-7601BB9C6B17Q36474050-59EED0AF-3BFF-44FC-B558-9BE52268A42EQ36777485-757489C9-593B-4351-9B3C-AEFADC06C953Q38202155-F40521E3-B6A1-468A-AFF3-39717DE09C47Q40577820-3C8F4EFD-2B65-4BA9-930D-5A5E72A7B81BQ42261486-93CA5E3B-272D-42C0-9EA8-2E4F0E54AE94Q47158332-5DCDA08B-72E5-4750-868B-D752AD902270
P2860
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Reduced intensity allogeneic h ...... rolimus-based GVHD prophylaxis
@ast
Reduced intensity allogeneic h ...... rolimus-based GVHD prophylaxis
@en
type
label
Reduced intensity allogeneic h ...... rolimus-based GVHD prophylaxis
@ast
Reduced intensity allogeneic h ...... rolimus-based GVHD prophylaxis
@en
prefLabel
Reduced intensity allogeneic h ...... rolimus-based GVHD prophylaxis
@ast
Reduced intensity allogeneic h ...... rolimus-based GVHD prophylaxis
@en
P2093
P2860
P1433
P1476
Reduced intensity allogeneic h ...... rolimus-based GVHD prophylaxis
@en
P2093
Anthony S Stein
David S Snyder
David Senitzer
Ji-Lian Cai
Joseph Alvarnas
Joseph Chao
Joycelynne M Palmer
Karen Chang
Margaret R O'Donnell
Pablo M Parker
P2860
P304
P356
10.1016/J.LEUKRES.2012.04.022
P577
2012-06-05T00:00:00Z